| SDH mutations in cancer C Bardella, PJ Pollard, I Tomlinson Biochimica et Biophysica Acta (BBA)-Bioenergetics 1807 (11), 1432-1443, 2011 | 447 | 2011 |
| Aberrant epithelial GREM1 expression initiates colonic tumorigenesis from cells outside the stem cell niche H Davis, S Irshad, M Bansal, H Rafferty, T Boitsova, C Bardella, E Jaeger, ... Nature medicine 21 (1), 62-70, 2015 | 278 | 2015 |
| Aberrant succination of proteins in fumarate hydratase‐deficient mice and HLRCC patients is a robust biomarker of mutation status C Bardella, M El‐Bahrawy, N Frizzell, J Adam, N Ternette, E Hatipoglu, ... The Journal of pathology 225 (1), 4-11, 2011 | 276 | 2011 |
| Common genetic variants at the 11q13. 3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression J Schödel, C Bardella, LK Sciesielski, JM Brown, CW Pugh, V Buckle, ... Nature genetics 44 (4), 420-425, 2012 | 178 | 2012 |
| Expression of Idh1R132H in the murine subventricular zone stem cell niche recapitulates features of early gliomagenesis C Bardella, O Al-Dalahmah, D Krell, P Brazauskas, K Al-Qahtani, ... Cancer cell 30 (4), 578-594, 2016 | 150 | 2016 |
| Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution M Kovac, C Navas, S Horswell, M Salm, C Bardella, A Rowan, M Stares, ... Nature communications 6 (1), 6336, 2015 | 128 | 2015 |
| Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression C Bardella, B Costa, P Maggiora, S Patane’, M Olivero, GN Ranzani, ... Cancer research 64 (15), 5154-5161, 2004 | 125 | 2004 |
| Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma D Krell, M Assoku, M Galloway, P Mulholland, I Tomlinson, C Bardella PloS one 6 (5), e19868, 2011 | 112 | 2011 |
| Oncogenic IDH1 mutations promote enhanced proline synthesis through PYCR1 to support the maintenance of mitochondrial redox homeostasis KER Hollinshead, H Munford, KL Eales, C Bardella, C Li, ... Cell reports 22 (12), 3107-3114, 2018 | 81 | 2018 |
| Expression profiling in progressive stages of fumarate-hydratase deficiency: the contribution of metabolic changes to tumorigenesis H Ashrafian, L O'Flaherty, J Adam, V Steeples, YL Chung, P East, ... Cancer research 70 (22), 9153-9165, 2010 | 77 | 2010 |
| IDH mutations in tumorigenesis and their potential role as novel therapeutic targets D Krell, P Mulholland, AE Frampton, J Krell, J Stebbing, C Bardella Future oncology 9 (12), 1923-1935, 2013 | 69 | 2013 |
| Anion-exchange chromatography mass spectrometry provides extensive coverage of primary metabolic pathways revealing altered metabolism in IDH1 mutant cells J Walsby-Tickle, J Gannon, I Hvinden, C Bardella, MI Abboud, A Nazeer, ... Communications biology 3 (1), 247, 2020 | 68 | 2020 |
| ERα as ligand-independent activator of CDH-1 regulates determination and maintenance of epithelial morphology in breast cancer cells MD Cardamone, C Bardella, A Gutierrez, L Di Croce, MG Rosenfeld, ... Proceedings of the National Academy of Sciences 106 (18), 7420-7425, 2009 | 57 | 2009 |
| p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy‐induced apoptosis N Coltella, A Rasola, E Nano, C Bardella, M Fassetta, N Filigheddu, ... International journal of cancer 118 (12), 2981-2990, 2006 | 54 | 2006 |
| Bone morphogenetic protein and Notch signalling crosstalk in poor‐prognosis, mesenchymal‐subtype colorectal cancer S Irshad, M Bansal, P Guarnieri, H Davis, A Al Haj Zen, B Baran, ... The Journal of pathology 242 (2), 178-192, 2017 | 50 | 2017 |
| Advances in research of adult gliomas A Finch, G Solomou, V Wykes, U Pohl, C Bardella, C Watts International journal of molecular sciences 22 (2), 924, 2021 | 45 | 2021 |
| Cells lacking the fumarase tumor suppressor are protected from apoptosis through a hypoxia-inducible factor-independent, AMPK-dependent mechanism C Bardella, M Olivero, A Lorenzato, M Geuna, J Adam, L O'Flaherty, ... Molecular and cellular biology 32 (15), 3081-3094, 2012 | 39 | 2012 |
| The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo C Bardella, D Dettori, M Olivero, N Coltella, M Mazzone, MF Di Renzo Clinical cancer research 13 (7), 2191-2198, 2007 | 33 | 2007 |
| Serum-and glucocorticoid-induced kinase Sgk1 directly promotes the differentiation of colorectal cancer cells and restrains metastasis LYW Lee, C Woolley, T Starkey, S Biswas, T Mirshahi, C Bardella, ... Clinical Cancer Research 25 (2), 629-640, 2019 | 23 | 2019 |
| Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors R Reinbold, IC Hvinden, P Rabe, RA Herold, A Finch, J Wood, M Morgan, ... Nature Communications 13 (1), 4785, 2022 | 18 | 2022 |
James McCullaghUniversity of OxfordVerified email at chem.ox.ac.uk
